Utilization and Predictors of PPI Co-Prescription in Warfarin-Treated Patients: Opportunities for Clinical Pharmacy Intervention
Main Article Content
Keywords
diabetes, ischemic heart disease, clopidogrel
Abstract
Background: Warfarin is recommended for several diseases, but it may cause bleeding particularly gastrointestinal bleeding. Proton pump inhibitor (PPI) is recommended in five conditions such as history of peptic ulcer disease, co-administration of antiplatelet, NSAIDs, or corticosteroids. There is limited data on PPI prophylaxis in patients with warfarin treatment with these five conditions. Objective: This study aimed to find additional predictors for PPI prophylaxis in patients who received warfarin therapy with any other recommended factors. Methods: This study was a retrospective cohort study conducted on hospital database of Khon Kaen University, Thailand. The inclusion criteria were adult patients who received warfarin therapy with any indications and were indicated for PPI prophylaxis by presence of one of any recommended factors mentioned above. Rates of PPI prophylaxis in the five conditions and clinical factor predictive PPI prescription were analyzed. Results: There were 1,789 patients who required PPI prevention while taking warfarin. The mean age of all patients was 70.45 year with a proportion of male patient of 51.87%. Of those, 611 patients (34.15%) received PPI prevention. According to the recommended factors, the PPI group had higher proportions of patients with age of more than 65 years (80.36% vs 73.60%), uncomplicated peptic ulcer disease (2.95% vs 0.68%), and concomitant corticosteroid (27.66% vs 12.31%) than the non-PPI group significantly. Concomitant antiplatelet and NSAIDs were not significant (p value = 0.665 and 0.458). Several predictors for PPI prophylaxis were identified such as diabetes, ischemic heart disease, treatment with clopidogrel, or internists as a primary physician. Conclusions: PPI prophylaxis in patients treated with warfarin was low at 34.15%. Predictors both positively and negatively of PPI prophylaxis were identified in five categories. Physicians who treat patients with warfarin therapy should be acknowledged on PPI prophylaxis appropriately. Additionally, these findings highlight the need for pharmacy-led interventions, such as clinical audits or risk assessment tools, to ensure appropriate gastroprotection in patients on warfarin.
References
2. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118(3):321–33. doi: 10.1016/j.thromres.2005.08.007
3. Ludden-Schlatter A, Stevermer JJ. PURLs: The benefits—and limits—of PPIs with warfarin regimens. J Fam Pract. 2017;66(11):694–6.
4. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–17. doi: 10.1016/j.jacc.2008.08.002
5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S–198S. doi: 10.1378/chest.08-0670
6. Shimomura A, Nagata N, Shimbo T, Sakurai T, Moriyasu S, Okubo H, et al. New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study. J Gastroenterol Hepatol. 2018;33(1):164–71. doi: 10.1111/jgh.13830
7. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. Gastroenterology. 2016;151(6):1105–1112.e10. doi: 10.1053/j.gastro.2016.08.054
8. Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021;85:1–13. doi: 10.1016/j.ejim.2020.11.014
9. Sharma R, Roy A, Ramos C, Rosenberg R, Garcia-Carrasquillo R, Lebwohl B. Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation. Therap Adv Gastroenterol. 2017;10(5):387–96. doi: 10.1177/1756283X17694807
10. Kurlander JE, Gu X, Scheiman JM, Haymart B, Kline-Rogers E, Saini SD, et al. Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. Vasc Med. 2019;24(2):153–5. doi: 10.1177/1358863X18815971
11. de Jong HJI, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MGH. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open. 2013;3(7):e003044. doi: 10.1136/bmjopen-2013-003044
12. Awaisu A, Hamou F, Mekideche L, El Muabby N, Mahfouz A, Mohammed S, et al. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar. Int J Clin Pharm. 2016;38(2):353–61. doi: 10.1007/s11096-016-0250-4
13. Bassand J-P, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021;5(4):1081–91. doi: 10.1182/bloodadvances.2020003560
14. Tang J, Sharma U, Desai S, Molnar J, Perlmuter L, Feller A, et al. A Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding. Cureus. 2021;13(1):e12624. doi: 10.7759/cureus.12624
15. Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54(14):1293–302. doi: 10.1016/j.jacc.2009.07.019
16. Boban M, Zulj M, Persic V, Medved I, Zekanovic D, Vcev A. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia. Int J Cardiol. 2016;219:277–81. doi: 10.1016/j.ijcard.2016.06.058
17. Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv. 2011;4(4):365–80. doi: 10.1016/j.jcin.2010.12.009
18. Li H, Li N, Jia X, Zhai Y, Xue X, Qiao Y. Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study. Front Pharmacol. 2022;13:881063. doi: 10.3389/fphar.2022.881063
19. Liu P, Li G, Wu Q, Han M, Zhang C. Analysis of inappropriate prophylactic use of proton pump inhibitors during the perioperative period: an observational study. Perioper Med (Lond). 2024;13(1):19. doi: 10.1186/s13741-024-00376-w
20. Panni U, Srivastava R, Bewley A, Williams GA, Fields RC, Sanford DE, et al. Postoperative Proton Pump Inhibitors are associated with a significantly higher rate of delayed gastric emptying after pancreatoduodenectomy. HPB (Oxford). 2023;25(6):659–66. doi: 10.1016/j.hpb.2023.02.015
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.